MNTA  Momenta Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.57 (-5.84%)

Company Metrics

  • P/E 13.83
  • P/S 7.42
  • P/B 1.80
  • EPS -1.32
  • Cash ROIC -52.09%
  • Cash Ratio 9.03
  • Dividend 0 / N/A %
  • Avg. Vol. 628,202.00
  • Shares 68.14M
  • Market Cap. 626.19M

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Momenta Pharmaceuticals Inc.: Momenta Pharmaceuticals Reports First Quarter ...
The Wall Street Transcript - 15 hours ago
"Since the beginning of 2016, Momenta has made steady progress in each of our business areas," said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. "Our biosimilars pipeline continues to advance. The pivotal trial ...
Stock in Queue: Momenta Pharmaceuticals Inc. (MNTA) - CWRU Observer
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) To Report Earnings - Risers & Fallers
Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Motley Fool - Mar 4, 2016
What: Shares of Momenta Pharmaceuticals (NASDAQ:MNTA), a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P ...
Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today
Motley Fool - Feb 18, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) is down 11% at 12:00 p.m. EST Thursday after releasing fourth quarter earnings this morning.
Craig Wheeler Sold 1688 Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) -
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q4 2015 Results ... - Seeking Alpha
Why Momenta Pharmaceuticals, Inc. Was Up Today
Motley Fool - Jan 8, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) was up as much as much as 11.7% today, eventually finishing up 6.8% after announcing a deal with Mylan (NASDAQ:MYL) to develop six biosimilar products.
Momenta, Mylan to Jointly Develop Six Biosimilars - Wall Street Journal
Momenta (MNTA) Collaborates with Mylan for 6 Biosimilars -
Momenta Pharmaceuticals, Inc. (MNTA) Stock Price Down 3.4% on Insider Selling
The Vista Voice - Apr 21, 2016
Momenta Pharmaceuticals logo Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was down 3.4% during mid-day trading on Wednesday after an insider sold shares in the company, MarketBeat.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Updated Broker Ratings - Risers & Fallers
John E. Bishop Sells 2843 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock - Web Breaking News
Momenta Pharmaceuticals, Inc. (MNTA) Position Held by Dimensional Fund Advisors LP
South Florida Hedge Fund Managers - Apr 5, 2016
Momenta Pharmaceuticals logo Dimensional Fund Advisors LP maintained its position in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) during the fourth quarter, Holdings Channel reports. The institutional investor owned 961,474 shares of the ...
Momenta Pharmaceuticals (MNTA) Is Strong On High Volume Today - Apr 4, 2016
This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, MOMENTA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and ...
Stock to Watch For Earnings: Momenta Pharmaceuticals Inc (MNTA)
CWRU Observer - Apr 18, 2016
Momenta Pharmaceuticals Inc. (MNTA) is expected to report Q1 earnings estimated on Tuesday 05/03/2016. The company operates in the Drugs - Generic industry.
Here's Why Momenta Pharmaceuticals, Inc. Shares Took Off Today
Motley Fool - Jun 1, 2015
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib ... - GlobeNewswire (press release)
Momenta Pharmaceuticals, Inc. Pushes Forward
Motley Fool - Nov 5, 2014
At this point, earnings calls for Momenta Pharmaceuticals (NASDAQ:MNTA) are more an opportunity to update investors than to report revenue and earnings.